Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Rhea-AI Summary

Precigen (NASDAQ: PGEN) announced its participation in two upcoming virtual fireside chats to discuss their recently FDA-approved therapy for adult recurrent respiratory papillomatosis. The first event, hosted by Jennifer Kim of Cantor, is scheduled for August 27, 2025, while the second chat, moderated by Dr. Swayampakula Ramakanth of H.C. Wainwright, will take place on September 2, 2025.

Both events will feature presentations from Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer. Investors can access the live webcasts through Precigen's investor relations website.

GERMANTOWN, Md., Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that Precigen will participate in two upcoming virtual fireside chats hosted by Jennifer Kim of Cantor, and Swayampakula Ramakanth, PhD, of H.C. Wainwright to discuss the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis.

Cantor Virtual Fireside Chat
August 27, 2025, 11 AM – 12 PM ET
Host: Jennifer Kim, Biotech Analyst, Cantor
Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen

H.C. Wainwright Virtual Fireside Chat
September 2, 2025, 11 AM – 12 PM ET
Moderator: Swayampakula Ramakanth, PhD, Managing Director, Equity Research, H.C. Wainwright
Participants: Helen Sabzevari, PhD, President and CEO, Precigen and Phil Tennant, Chief Commercial Officer, Precigen

Participants may access the live webcasts of the virtual events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision^®
Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com

Media Contact:
Donelle M. Gregory
press@precigen.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-upcoming-virtual-fireside-chats-hosted-by-cantor-and-hc-wainwright-302537276.html

SOURCE Precigen, Inc.

FAQ

When are Precigen's (PGEN) upcoming virtual fireside chats scheduled for?

Precigen has two upcoming fireside chats: one on August 27, 2025 hosted by Cantor, and another on September 2, 2025 hosted by H.C. Wainwright, both from 11 AM to 12 PM ET.

Who will be presenting at Precigen's (PGEN) virtual fireside chats?

The presentations will feature Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer of Precigen.

What will be discussed at Precigen's (PGEN) virtual fireside chats?

The fireside chats will discuss Precigen's recently FDA-approved therapy for adults with recurrent respiratory papillomatosis, which is the first and only FDA-approved treatment for this condition.

How can investors access Precigen's (PGEN) virtual fireside chats?

Investors can access the live webcasts through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.